Data Support Liso-Cel for Relapsed or Refractory CLL/SLL
New research suggests that lisocabtagene maraleucel (liso-cel) is a potential treatment option for relapsed or refractory CLL/SLL.
New research suggests that lisocabtagene maraleucel (liso-cel) is a potential treatment option for relapsed or refractory CLL/SLL.
Most NCCN cancer centers have been affected by shortages of the chemotherapy drugs carboplatin and cisplatin, a survey suggests.